Equities

Daito Pharmaceutical Co Ltd

Daito Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)2,170.00
  • Today's Change-33.00 / -1.50%
  • Shares traded22.80k
  • 1 Year change+12.38%
  • Beta0.8087
Data delayed at least 20 minutes, as of Nov 08 2024 06:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy1
Outperform1
Hold0
Sell0
Strong Sell0

Share price forecast in JPY

The one analyst offering a 12 month price target expects Daito Pharmaceutical Co Ltd share price to rise to 2,780.00 in the next year from the last price of 2,170.00.
High28.1%2,780.00
Med28.1%2,780.00
Low28.1%2,780.00

Dividends in JPY

In 2024, Daito Pharmaceutical Co Ltd reported a dividend of 60.00 JPY, which represents a 10.00% increase over last year. The analyst covering the company expects dividends of 70.00 JPY for the upcoming fiscal year, an increase of 16.67%.
Div growth (TTM)10.00%
More ▼

Earnings history & estimates in JPY

Daito Pharmaceutical Co Ltd reported annual 2024 earnings of 210.00 per share on Jul 12, 2024.
Average growth rate-6.20%
More ▼

Revenue history & estimates in JPY

Daito Pharmaceutical Co.,Ltd. had 1st quarter 2025 revenues of 12.68m. This was 4.11% above the prior year's 1st quarter results.
Average growth rate+1.50%
Daito Pharmaceutical Co.,Ltd. had revenues for the full year 2024 of 46.90m. This was 3.98% above the prior year's results.
Average growth rate+1.31%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.